September 2014

New Product - Mirvaso

Mirvaso (brimonidine) contains a selective α₂-adrenergic receptor agonist that is 1000-fold more selective for the α₂-adrenergic receptor than the α₁-adrenergic receptor. Topical facial application of a highly selective α₂-adrenergic receptor agonist is intended to reduce erythema through direct cutaneous vasoconstriction. Mirvaso is indicated for the treatment of facial erythema of rosacea in adults. It is contraindicated in children under 18 years of age; therapy with concomitant monoamine oxidase inhibitor (MAOI) and with tricyclic or tetracyclic antidepressants, which affect noradrenergic transmission. Mirvaso is available as a gel containing brimonidine tartrate 5 mg/g (≡ brimonidine 3.3 mg/g) in a 30 g tube in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au